PubMed
Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I
Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996
Compare
IGF-1 DES vs Liraglutide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
IGF-1 DES
2337 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 51% · Mixed 32% · Unfavorable overall 17%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Skin appearance
48
Appetite control
39
Energy
127
Mood
93
Focus
112
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
144
GI discomfort
118
Dizziness
92
Fatigue
89
Nausea
111
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.05–2 mg
0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
18
0.4–0.6 mg
14
0.6–1 mg
8
1–2 mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing21stacking19side effects17igf-1 des20
How repeat users are trending
Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 23 days · Based on 514 repeat reporters
Liraglutide
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
2
2+ mg
4
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (12)
Published sources linked on the IGF-1 DES and Liraglutide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice
Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990
- Wiki study page →Source
PubMed
In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness
Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995
- Wiki study page →Source
PubMed
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997
- Wiki study page →Source
PubMed
Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats
Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992
- Wiki study page →Source
ClinicalTrials.gov
des(1-3)IGF-1 / IGF-1 DES studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
FDA Drug Label
SAXENDA (liraglutide) injection — Prescribing Information
Novo Nordisk. FDA Drug Label. 2014
- Wiki study page →Source
FDA Drug Label
VICTOZA (liraglutide) injection — Prescribing Information
Novo Nordisk. FDA Drug Label. 2010
- Wiki study page →Source
PubMed
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)
Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016
- Wiki study page →Source
PubMed
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)
Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015
- Wiki study page →Source
PubMed
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022
- Wiki study page →Source
PubMed
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
Garvey WT, Birkenfeld AL, Dicker D, et al. Diabetes care. 2020